

IMMUNOGEN INC  
Form 8-K  
December 07, 2009

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **December 5, 2009**

**ImmunoGen, Inc.**

(Exact name of registrant as specified in its charter)

**Massachusetts**  
(State or other  
jurisdiction of  
incorporation)

**0-17999**  
(Commission File  
Number)

**04-2726691**  
(IRS Employer  
Identification No.)

**830 Winter Street, Waltham, MA 02451**

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: **(781) 895-0600**

## Edgar Filing: IMMUNOGEN INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**ITEM 7.01 REGULATION FD DISCLOSURE**

On December 5, 2009, interim clinical data from a BT-062 Phase I clinical trial were presented at the annual meeting of the American Society of Hematology (ASH) held in New Orleans, LA. BT-062 comprises a CD138-targeting antibody belonging to Biotest AG with ImmunoGen's DM4 cancer-cell killing agent attached using an engineered linker. Biotest is developing BT-062 under a collaboration agreement with ImmunoGen, and has issued a press release on the study data reported.

These clinical data are from a Phase I dose-escalation trial evaluating BT-062 when administered once every three weeks to patients with relapsed and/or refractory multiple myeloma. The objective of the trial is to identify the maximum tolerated dose, dose-limiting toxicities and pharmacokinetics of BT-062 with this administration schedule as well as to obtain information on its clinical efficacy.

At the time of data cut-off for presentation, 25 patients had received one of seven dose levels of BT-062 ranging between 10 to 200 mg/m<sup>2</sup>. These patients previously had been treated with a median of seven prior therapies, with approximately one-third of the patients having received at least ten prior therapies.

BT-062 was found to have an acceptable and manageable toxicity profile. The maximum tolerated dose was established to be 160 mg/m<sup>2</sup> with this administration schedule with mucositis reported as the dose-limiting toxicity.

Seventeen (17) of these patients had received more than one treatment cycle, were efficacy-evaluable, and were no longer undergoing treatment at the time of data cut-off for presentation, with three other patients still receiving BT-062. Two of the 17 patients had objective responses (one partial response and one minimal response) and remained on treatment with BT-062 for at least 12 weeks. Seven other patients had stable disease for more than six weeks. Overall, 53% of these seventeen patients had a sustained delay in the progression of their cancer in this Phase I study of BT-062.

Biotest noted that on the basis of the encouraging tolerability and efficacy seen to date, it plans to assess BT-062 using a more frequent dosing regimen.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ImmunoGen, Inc.**  
(Registrant)

Edgar Filing: IMMUNOGEN INC - Form 8-K

Date: December 7, 2009

/s/ Gregory D. Perry  
Gregory D. Perry  
Senior Vice President and Chief Financial Officer

2

---